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Résumé: 
Prévention secondaire des fractures ostéoporotigues : place à l'amélioration des 
pratiques 
Introduction : l'ostéoporose est une maladie fréquente, invalidante, sous-
diagnostiquée et sous-tr,aitée, alors qu'il existe des évidences cliniques, densitométriques 
et biologiques de l'efficacité de la prévention secondaire. 
Matériel et méthode : dans cette étude, nous décrivons les habitudes de prescription 
de traitements en prévention secondaire dans les 6 mois qui suivent une fracture de 
fragilité et définissons les catégories de femmes recevant ou non un traitement, selon le 
type de fractures, les antécédents fracturaires et les données socio-démographiques. Il 
s'agit d'une étude suisse de cohorte, prospective de 7609 femmes de 70 ans et plus, 
suivies de 1998 à 2000. Deux groupes de patientes ont été analysés : celles avec un 
événement fracturaire durant le suivi (3 sous-groupes de fractures ont été considérés : 
fractures vertébrales, fractures du radius distal et fractures de l'humérus proximal) et 
celles sans fractures durant le suivi (groupe contrôle). 
La détermination des événements fracturaires et l'instauration d'un traitement s'est faite 
par l'envoi aux patientes et à leurs médecins traitants d'un questionnaire structuré. Dans 
cette étude, le but primaire - est de décrire les attitudes médicales de prévention 
secondaire, le but secondaire d'analyser les motifs de décision thérapeutique (type de 
fracture, antécédents de fractures), alors que le but tertiaire cherche à caractériser les 
femmes non traitées. 
Résultats, discussion : 7354 femmes ont été incluses dans cette étude, 183 dans le 
groupe fracture et 7171 dans le groupe contrôle. Le suivi moyen a été de 21 mois. 
L'introduction d'un traitement est restée rare dans chaque catégorie de fracture et a été 
plus importante pour le sous-groupe avec fracture vertébrale (p<0.001 ). La seule donnée 
associée à l'adjonction d'un traitement a été la présence d'un antécédent anamnestique 
de fracture vertébrale. 
La description des attitudes thérapeutiques après une fracture de fragilité, a montré que 
44 % des femmes ne reçoivent aucun traitement en prévention secondaire. Seule la 
fracture vertébrale et les antécédents de fracture vertébrale entraînent une modification 
de l'attitude thérapeutique des médecins traitants mais de façon encore insuffisante 
puisque plus de 50 % des femmes avec une fracture de vertèbre n'ont aucun 
changement dans leur prise en charge. Les femmes non traitées ne différaient pas des 
autres sur un plan socio-démographique. 
Le nombre de patientes dans chaque sous-groupe est relativement faible ce qui limite la 
puissance statistique de l'analyse. Les données consistent essentiellement en du «self-
reporting » ce qui peut limiter la signification de celles-ci. 
Les résultats sont cependant suffisamment inquiétants pour que de nouvelles campagnes 
d'information soient lancées auprès des médecins de premiers recours quant à la 
nécessité d'instaurer un traitement efficace lors de la survenue d'une fracture clinique ou 
radiologique chez une femme en post-ménopause. 
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Introduction 
Osteoporosis, defined as a diminution of bone minerai density (BMD) and a 
deterioration of micro-architecture of bone tissue, leads to an increase in bone fragility 
and risk of fracture [1]. ln postmenopausal women, the lifetime risk of hip and vertebral 
fractures ranges between 15% and 30% [2, 3]. A 25% to 30% increase in hip fractures in 
Western countries is expected within the next decades because of the ageing populations 
[4-6]. lt has been shown that osteoporotic fractures have a major impact in terms of 
morbidity and mortality, particularly after hip fracture. For the latter, the one-year mortality 
is about 20% higher compared to age-specific mortality [7-9]. For these reasons, 
preventive measures are urgently needed. 
For a given patient, the probability of osteoporotic fractures can be assessed, not _ 
only by measurement of bone minerai density (BMD), but also by the presence of clinical 
risk factors [1 O], particularly prevalent fragility fractures [11, 12, and 13]. Previous 
vertebral, hip, forearm or humerai fracture is associated with a two to four-fold increased 
risk of subsequent osteoporotic fracture [14-18]. 
Many clinical trials have shown the efficacy of several secondary prevention 
therapies. Whereas supplements of calcium decreased incident vertebral fracture rate in 
vitamin 0-replete elderly patients in one study [19], calcium associated with vitamin D 
supplementation have proven in several studies to be beneficial in elderly people for bone 
loss and fracture prevention, particularly in institutionalized subjects [20-26]. These 
supplementations are as cost-effective as treatments for other common chronic conditions 
such as hypertension [27]. Furthermore, the use of specific agents such as 
bisphosphonates, calcitonin, and raloxifen [28-39] result in about a 30% to 60% decrease 
of new osteoporotic fractures in women with pre-existing fractures. This is particularly true 
for vertebral fractures. However, only a minority of postmenopausal women received a 
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specific therapy during the year after a fracture, and non vertebral fractures are rarely 
associated with secondary prevention compared to vertebral fractures [40, 41]. As it has 
been shown that to treat post-menopausal osteoporotic women with prevalent vertebral or 
non vertebral fracture could have a significant cost-effective impact [42-44], emphasis 
should therefore be given to secondary prevention. lt is obvious that specific strategies 
focusing on a primary prevention in order to avoid the first fracture remain the major 
endpoint of osteoporosis management. 
The first endpoint of this study was to assess the self-reported prescription of 
secondary prevention therapy, if any, after the occurrence of an osteoporotic fracture in a 
sample of elderly Swiss women. The second endpoint was to understand the reason why 
a patient will receive a secondary preventive treatment in terms of fracture-type or 
prevalent fracture. The tertiary endpoint was to identify some socio-demographic data 
able to interfere with a good medical management after a fragility fracture. To our 
knowledge, no prospective population-based study has assessed the use of secondary 
prevention in elderly women after a fragility fracture. 
For this purpose, we used the data of the large prospective Swiss Evaluation of the 
Methods of Measurement of Osteoporotic Fracture Risk (SEMOF) study. 
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Subjects and methods 
The SEMOF study is a prospective multicenter study which aim was to compare 
the predictive value for hip fracture risk of three different bone ultrasound devices in a 
sample of Swiss women aged 70 and older [45,46]. Participants were recruited from 
January 1998 to summer 1999 from population-based listings in 10 areas a cross 
Switzerland. The study included women who were able to walk and independently 
participate in daily activities, and excluded those with a history of hip fracture, bilateral hip 
replacement, renal failure, active cancer or dementia. Fifty-nine thousand two hundred 
and ninety-eight women were randomly selected and informed by mail about the SEMOF 
study. From these women, 8680 were interested and gave their written consent for their 
participation, which represent a participation rate of 14.6%. One thousand and seventy-
one women were not assessed because they secondarily refused to corne to the first visit, 
had one or more exclusion criteria, particularly a prevalent hip fracture, or died during the 
interval, and 255 women didn't answer to the first questionnaire after 6 months and were 
considered as lost to follow-up. Participants were asked to visit one of the 10 clinical 
centers to undergo a face-to-face interview, a physical examination and bone ultrasound 
investigations. 
Structured questionnaires designed to collect sociodemographic and clinical 
variables were pre-tested and presented elsewhere [45]. Women were asked whether 
their general practitioner had diagnosed them as having osteoporosis. Data on the 
incidence of an osteoporotic fracture and prescription of calcium and vitamin D 
supplementation, or any other specific therapy against osteoporosis (bisphosphonates, 
raloxifen and calcitonin) were extracted from the 6-monthly follow-up questionnaires. HRT 
was not included as a specific therapy since it is not been shown as an efficient therapy 
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for patients older than 75. For a participant, the duration of follow-up corresponded to the 
period from the inclusion to the fracture event (new fracture). 
We assessed the validity of the information given in the questionnaire by 
comparing participants' answers with the information provided by participants' physicians 
from a random sample of women. From the 58 questionnaires mailed to participants' 
physicians, 52 completed questionnaires were returned (response rate 89.7 %). The 
correlation between participant and physician information was rated as good for data 
about specific anti-osteoporotic therapy (kappa value 0.80) and medium for data about 
calcium and vitamin D therapy (kappa value 0.44 and 0.29). The latter discrepancy may 
partially be due to the fact that many women were unaware that their calcium tablets also 
contained vitamin O. During the study, each participant received by mail a questionnaire 
every 6 months. These questionnaires registered any changes in medical conditions 
which had occurred during the intervals, particularly any illness, modification or initiation 
of medication, and incident fracture, with its precise localization and its trauma level. Low 
trauma fractures were defined as spontaneous or as the consequence of a fall from 
standing height or less. We excluded women whose fractures might have been due to 
metastatic cancer or high-energy trauma. Each fracture was confirmed and detailed 
(circumstances of occurrence and trauma level) in a medical report from the physician in 
charge of the patient. 
Ali participants who reported the occurrence of a vertebral, humerai or forearm 
fracture during one of the 6-monthly follow-up-questionnaire sent from January 1998 and 
31 st July 2000 were considered as cases. The contrai group comprised all women who 
reported no fractures during the same follow-up period. The endpoint of the present study 
was to assess usual medical practice during the 6 months following the occurrence of a 
typical osteoporotic fracture. As incident hip fracture was the primary endpoint of this 
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study, women with such a fracture were no more assessed with follow-up questionnaires. 
Therefore, hip fractures were not included in this analysis. 
Comparisons of means were performed with the Wilcoxon rank sum test, and 
frequencies were compared with the Pearson chi-square test. Confounding factors (age, 
diagnosis of osteoporasis and duration of follow-up) for prevalence of fractures before 
baseline (prevalent fractures) and number of prescribed treatments at the time of the 
questionnaire (calcium, vitamin D or specific therapy), have been contralled by randomly 
resampling according to a pair matched-scheme. The resampling was repeated 1 OO 
times. The distribution of the frequencies of the events of interest in the resampled contrai 
groups pravides a test for comparing the fractured and contrai graups under the null 
hypothesis that the confounding factors exist at the same levels in both graups. For 
example, to compare the prevalence of prior fracture in the two graups, the following rule 
is applied: if the prevalence in the fractured graup is larger than 98 of the 1 OO simulated 
prevalences, it is concluded that the prevalence is higher in the fractured graup. This rule 
pravides a simulation based test, with an errar type 1 prabability less than 0.02. The HRT 
rate and the mean number of treatments have been compared in a similar fashion. 
Statistical analysis was performed using the Stata 8.1 statistical software (Stata Corp., 
College Station, TX, USA). 
The study pratocol of the SEMOF study was appraved by the ethics committee of 
the Swiss Academy of Medical Sciences. 
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Results 
Seven thousand three hundred and fifty-four women were prospectively followed 
during a mean period of 21 months, which represents 12'870 person-years. One hundred 
and eighty-three women reported a fracture during this period (47 women with a vertebral 
fracture, 94 with a forearm fracture, and 42 with a humerai fracture) and constituted the 
fracture group. The 7171 women without any incident fracture comprised the contrai 
group. Baseline characteristics of the women are presented in table 1. There was no 
difference in mean BMI between the 2 groups, but we observed significant differences in 
mean age, proportion of diagnosis of osteoporosis, prevalent fractures, HRT use, calcium 
and vitamin D supplementations, and anti-osteoporotic fracture specific treatment (i.e., 
biphosphonates, calcitonin, or raloxifen). More than 90% of the prescribed drugs were 
bisphosphonates. After adjusting for age and diagnosis of osteoporosis, it was confirmed 
that the fracture group was more likely to have experienced prevalent fracture(s), whereas 
the use of each therapy was not anymore significantly different between the two groups. 
Participants with a new forearm or humerai fracture had an unremarkable history of any 
type of prevalent fracture, whereas those with new vertebral fracture had significantly 
more prevalent vertebral fractures (prevalent vertebral fracture was 25% for new vertebral 
fracture, 15% for new forearm fracture and 5% for new humerai fracture, p=0.025). 
Notably, in bath groups (fracture and contrai groups), a slight increase in the 
frequency of treated women occurred during the follow-up, compared with baseline data 
(table 2). 
The frequency of initiation of a secondary prevention therapy during the 6 months 
following a new fracture varied with the fracture type and was more commonly prescribed 
after a new vertebral fractures compared to forearm or humerai fracture (p<0.001 ). The 
prescription of a specific treatment against osteoporosis (bisphosphonates, raloxifen, 
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calcitonin) after the occurrence of a new fracture was of 42%, 9% and 12%, for a new 
vertebral, forearm and humerai fracture, respectively (Figure 1). Considering ail types of 
fracture, it was of 18%. Calcium supplementation was prescribed to 73%, 16%, and 28% 
of the women with new vertebral, forearm and humerai fractures, respectively, and 
vitamin D supplementation to 67%, 16% and 27% of the women (Figure 2). When the 
women without any initiation of treatment after an osteoporotic fracture were 
characterized by clinical factors detailed in table 1, two factors appeared to be 
significantly associated with such an inadequate care: not having a previous diagnosis of 
osteoporosis (53% in the untreated group compared to 11 % in the treated group), nor a 
past vertebral fracture (21 % compared to 5%). There was no difference in any socio-
demographic data such as education, lifestyle situation or land versus city-area living 
(data not shown). 
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Discussion 
Whereas vertebral fracture are clearly associated with osteoporosis, we showed in 
this study that only 18% of the women included in the prospective SEMOF study received 
an adequate treatment within 6 months after they suffered ·a clinical fragility fracture. 
Whereas 42% of the women were adequately treated after a clinical vertebral fracture, 
forearm and humerai fractures were not associated with the need of an anti-osteoporotic 
treatment, with a percentage of treated women of 9% and 12% respectively, even with the 
knowledge of prevalent fractures. 
Contrarily to specific treatment against osteoporosis, calcium and/or vitamin D 
supplementations were easily prescribed in this elderly women population after the 
occurrence of any fracture event. However, as only vertebral fracture was corisidered as 
typically due to osteoporosis, differences were also observed in function of the type of 
fracture. Calcium supplementation was prescribed in 67% of the women after of clinical 
vertebral fracture, but in only 16% after a forearm fracture and 28% after a humerai 
fracture. For vitamin D supplementation, these percentages were of 67%, 16% and 27%, 
respectively. 
This low rate of specific treatment initiation after fragility fractures clearly illustrates 
the lack of recognition of osteoporosis and, more importaMly, that even if an osteoporotic 
fracture is diagnosed (as reported by the participants), the current medical practice don't 
follow the international guidelines for secondary prevention of fracture. 
Our results extend those obtained in other studies. Andrade et al. [30] 
retrospectively evaluated the use of drugs for treatment of osteoporosis (oestrogen 
replacement therapy, bisphosphonates, or calcitonin) during the year following a fracture 
of the hip, of the vertebra, or of the forearm in US women aged 60 years and aider. They 
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showed that the year following a vertebral fracture, only 44% of the women have received 
a treatment, which is in agreement with our data, this rate of treatment dropping to 23% 
after a fracture of the forearm, which is 2.5-fold higher compare to our results. These 
differences must be due to the tact that the women included in the SEMOF study were 10 
years older. ln a retrospective-controlled study on women older than 45 to 50 years, 
Badal et al. [31] showed that 60 to 80% of women with a vertebral or a distal fracture were 
not prescribed any treatment. 
ln another registry, our results also confirm that having suffered from a previous 
fracture is associated with a higher incidence of new fractures [47, 48]. 
The slight increase in frequency of treatments in both groups (women with and 
without fractures) during the time between joining the study to the first follow-up could be 
mainly explained by a « study-effect » on their physicians, who may became more 
concerned about their patients' therapies because of the inclusion of the patients in an 
osteoporosis-related study. 
Our study has several limitations. First, we used self-reported data. However, we 
found good agreement between reports of medications use and fracture history by 
patients and their physicians, and each new fracture was confirmed by a medical report. 
Furthermore, the validity of information on medications and previous fractures has also 
been previously demonstrated [49, 50]. Secondly, we based our analysis on a single 
report. However, such an approach has previously been shown to be adequate to 
ascertain clinical issues in elderly women [51-54]. Thirdly, a recall bias is possible, i.e., 
women who suffered from a fracture might recall a therapy linked to their treatment better 
than other participants. However, we did not find any differences between the 2 groups of 
women with respect to reporting of other crucial medical events, such as previous 
fractures. Furthermore, we excluded women with marked loss of intellectual function or 
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impaired cognition. Finally, with longer follow-up, it is possible that some of these women 
would eventually receive appropriate care at a later date. Nevertheless, a lack of 
appropriate care in the first months following an osteoporotic fracture has clear clinical 
impact in terms of risk of subsequent fracture, as 20% of subsequent vertebral fractures 
occur within the year after a vertebral fracture [55]. 
Although clinical guidelines for patient management after osteoporotic fracture are 
currently available [56-58], our data suggest that many physicians did not associate post-
menopausal low trauma fracture with the need of secondary prevention. 
ln conclusion, only women with a vertebral fracture appear to have been identified 
as suffering from osteoporosis. However, less than 50% of them receive a specific 
treatment against osteoporosis. This rate felt around 10% when fractures of the forearm 
or of the proximal humerus were considered. Use of calcium and vitamin D was more 
frequent after a vertebral fracture and the limiting factor of calcium/vitamin D introduction 
seemed also to be the recognition of an osteoporotic fracture. A very recent meta-analysis 
[59] has clearly shown the efficacy of calcium and vitamin D in sufficient doses in elderly 
institutionalised people (a 12% ail-type osteoporotic fractures reduction). As many studies 
have clearly demonstrated efficiency and cost-effectiveness of treatment against 
osteoporosis such as bisphosphonates and raloxifen, and now calcium and vitamin D, 
particularly after vertebral fracture, there is obviously a room for improvement in the 
management of osteoporosis. 
Maybe a good way to improve management of osteoporotic fractures could be an 
information campaign targeted at post-menopausal women, as it is done against breast 
cancer. Every low trauma fracture should be appropriately investigated to confirm its 
osteoporotic nature and accordingly should be appropriately treated (pharmacologically 
and non-pharmacologically with physical measures against falls). 
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Table 1: Baseline characteristics of the 7354 study participants 
Fractured group Control group P value 
N= 183 N= 7171 
Age, mean, years 76.1 75.2 <0.001 
Body Mass Index (kg/m;,() 25.7 26 0.37 
HRT (%) 5 11 0.007 
Calcium supplements '(%) 34 20 <0.001 
Vitamin D supplements 21 13 0.002 
(%) 
Specific osteoporosis 9 4 <0.001 
therapy 1 % 
Clinical diagnosis of 34 18 <0.001 
osteoporosis (%) 
Prevalence of past 65 51 <0.001 
fracture(%) 
Vertebral 15 4 0.002 
Forearm 29 21 <0.001 
Others 44 36 0.04 
HRT =Hormone replacement therapy 
1l specific therapy includes bisphosphonates, raloxifen, calcitonin 
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Table 2: "Study-effect": Observation of increase of specific treatment against 
osteoporosis in both groups after 6 months of follow-up. 
Fracture group Contrai group 
(N) (N) 
Baseline 9% (183) 4% (7124) 
6-monthly follow-up questionnaire 1 15% (159) 8 % (5737) 
6-monthly follow-up questionnaire 2 16% (153) 8% (5809) 
6-monthly follow-up questionnaire 3 21 % (140) 7% (4600) 
6-monthly follow-up questionnaire 4 19% (77) 7% (2038) 
6-monthly follow-up questionnaire 5 25%(12) 7% (346) 
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Figure 1: Initiation of a specific therapy after a 
new fracture 
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Figure 2: Women receiving a calcium/vitamin D 
supplementation after a new fracture 
percentage 
100~-~~~~~~~~~~~ 
80-+-~~~~~~~~~~~ 
of ail incident 60 
fractures 
reported 
40 
20 
0 
verte brai 
fracture 
forearm 
fracture 
type offracture 
humerai 
fracture 
11 calcium 
tm vitamin D 
18 
References: 
1. Anonymous, Consensus development conference: diagnosis, prophylaxis and 
treatment of osteoporosis. Am J Med 1993; 94:646-650. 
2. Cumming RG, Nevitt MC, Cummings SR. Epidemiology of hip fractures. Epidemiol 
Rev 1997;19:244-257. 
3. Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles, or vertebral 
fracture and coronary hearth disease among white postmenopausal women. Arch 
lntern Med 1989;149:2445-2448. 
4. Oden A, Dawson A, Dere W, Johnell 0, Jonsson B, Kanis JA. Lifetime risk of hip 
fractures is underestimated. Osteoporos lnt 1998;8:599-603. 
5. Nydegger V, Rizzoli R, Rapin CH, Vasey H, Bonjour JP. Epidemiology of fractures 
of the proximal femur in Geneva: Incidence, clinical and social aspects. Osteoporos 
lnt 1991 ;2:42-47. 
6. Bonjour JP, Burckhardt P, Dambacher M, Kraenzlin ME, Wimpfheimer C. 
Epidemiologie der Osteoporose. Schweiz Med Wschr 1997;127:659-667. 
7. Cooper C. The crippling consequences of fractures and their impact on quality of 
life. Am J Med 1997; 103:12S-19S. 
8. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D. Risk of mortality 
following clinical fractures. Osteoporos lnt 2000;11 :556-561. 
9. Lippuner K, Von Overbeck J, Perrelet R, Bosshard H, Jaeger P. Incidence and 
direct medical costs of hospitalizations due to osteoporotic fractures in Switzerland. 
Osteoporos lnt 1997;7:414-425. 
1 O. Kanis JA, Oden A, Johnell 0, Johansson H, De Laet C, Brown J, Burckhardt P, 
Cooper C, Christiansen C, Cummings S, Eisman JA, Fujiwara S, Gluer C, 
Goltzman D, Hans D, Krieg MA, La Croix A, McCloskey E, Mellstrom D, Melton LJ, 
19 
3rd, Pois H, Reeve J, Sanders K, SchoUAM, Silman A, Torgerson D, van Staa T, 
Watts NB, Yoshimura N. The use of clinical risk factors enhances the performance 
of BMD in the prediction of hip and osteoporotic fractures in men and women. 
Osteoporos lnt 2007;18:1033-1046. 
11. Ross PD. Risk factors for osteoporotic fracture. Endocrin Metab Clin 1998;27:289-
301. 
12. Ross PD. Prediction of fracture risk Il: Other risk factors. Am J Med Sei 
1996;312:260-269. 
13. Kanis JA, Johnell 0, De Laet C, Johansson H, Oden A, Delmas P, Eisman J, 
Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pois H, 
Reeve J, Silman A, Tenenhouse A. A meta-analysis of previous fracture and 
subsequent fracture risk. Bane 2004; 35:375-382. 
14. Mallmin H, Ljunghall S. Distal radius fracture is an early sign of general 
osteoporosis: Bane mass measurements in a population-based study. Osteoporos 
lnt 1994;4:357-361. 
15. Lauritzen JB, Schwarz P, McNair P, Lund B, Transbol 1. Radial and humerai 
fractures as predictors of subsequent hip, radial or humerai fractures in women, 
and their seasonal variation. Osteoporos lnt 1993;3:133-137. 
16. Gardsell P, Johnell 0, Nilsson BE, Nilsson JA. The predictive value of fracture, 
disease and falling tendency for fragility fractures in women. Calcified Tissue lnt 
1989;45:327-330. 
17. Kotowicz MA, Melton LJ Ill, Cooper C, Atkinson EJ, 0 Fallon WM, Riggs BL. Risk 
of hip fracture in women with vertebral fracture. J Bane Miner Res 1994;9:599-605. 
18. Klotzbuecher CM, Ross PD, Landsman PB, Abott TA, Berger M. Patients with prior 
fractures have an increased risk of futures fractures: a summary of the literature 
20 
and statistical synthesis. J Bone Miner Res 2000;15:721-739. 
19. Chevalley T, Rizzoli R, Nydegger V, Slosman D, Rapin CH, Michel JP, Vasey H, 
Bonjour JP. Effect of calcium supplements on femoral bone minerai density and 
vertebral fracture rate in vitamin-D-replete elderly patients. Osteoporos lnt 
1994;4:245-252. 
20. Chapuy MC, Ariot ME, Duboeuf F, Brun J, Crouzet B, Arnaud S, Delmas PD, 
Meunier PJ. Vitamin D3 and calcium to prevent hip fractures in the elderly women. 
N Engl J Med 1992;327:1637-1642. 
21. Recker RR, Hinders S, Davies KM, Heaney RP, Stegman MR, Lappe JM, Kimmel 
DB. Correcting calcium nutritional deficiency prevents spine fractures in elderly 
women. J Bane Miner Res 1996;11:1961-1966. 
22. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D 
supplementation on bone density in men and women 65 years of age or aider. N 
Engl J Med 1997;337:670-676. 
23. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 
1998;338:736. 
24. Meunier PJ. Calcium and vitamin D are effective in preventing fractures in elderly 
people by reversing senile secondary hyperparathyroidism. Osteoporos lnt 
1998;8:S1-S2. 
25. Papadimitropoulos E, Wells G, Shea B, Gillespie W, Weaver B, Zytaruk N, 
Cranney A, Adachi J, Tugwell P, Josse R, Greenwood C, Guyatt G. Meta-analyses 
of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of 
vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr 
Rev 2002;23:560-569. 
26. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-
21 
Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of 
randomized controlled trials. JAMA 2005;293:2257-2264. 
27. Jonsson B, Christansen C, Johnell 0, Hedbrandt J. Cost-effectiveness of fracture 
prevention in established osteoporosis. Osteoporos lnt 1995;5: 136-142. 
28. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, 
Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates 
AJ, LaCroix AZ. Effect of alendronate on risk of fracture in women with low bone 
density but without vertebral fractures. JAMA 1998;280:2077-2082. 
29. Ensrud KE, Black DM, Palermo L, Sauer OC, Barrett-Connor E, Quandt SA, 
Thompson DE, Karpf DB. Treatment with alendronate prevents fractures in women 
at highest risk: results from the Fracture Intervention Trial. Arch lntern Med 
1997; 157:2617-2624. 
30. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut 
Ill CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD. Effects of 
risedronate treatment on vertebral and nonvertebral fractures in women with 
postmenopausal Osteoporosis: A randomized controlled trial. JAMA 
1999;282:1344-1352. 
31. Chesnut Ill CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, Kiel D, 
LeBoff M, Maricic M, Miller P, Moniz C, Peacock M, Richardson P, Watts N, 
Baylink D. A randomized trial of nasal spray salmon calcitonin in postmenopausal 
women with established osteoporosis: the Prevent Recurrence of Osteoporotic 
Fractures Study. Am J Med 2000;109:267-276. 
32. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Genant HK, Christiansen C, 
Delmas PD, Zanchetta JR, Stakkestad J, Glüer CC, Krueger K, Cohen FJ, Eckert 
S, Ensrud KE, Avioli LV, Lips P, Cummings SR. Reduction of vertebral fracture risk 
22 
in postmenopausal women with osteoporosis treated with raloxifene. Results from 
a 3-years randomized clinical trial. JAMA 1999;282:637-645. 
33. McClung MR, Geusens P, Miller PD, Zippe! H, Bensen WG, Roux C, Adami S, 
Fogelman 1, Diamond T, Eastell R, Meunier PJ, Reginster JY. Effect of risedronate 
on the risk of hip fracture in elderly women. N Engl J Med 2001 ;344:333-340. 
34. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, 
Shea B, Tugwell P, Guyatt G. Meta-analyses of therapies for postmenopausal 
osteoporosis. Il. Meta-analysis of alendronate for the treatment of postmenopausal 
women. Endocr Rev 2002;23:508-516. 
35. Cranney A, Tugwell P, Adachi J, Weaver B, Zytaruk N, Papaioannou A, Robinson 
V, Shea B, Wells G, Guyatt G. Meta-analyses of therapies for postmenopausal 
osteoporosis. Ill. Meta-analysis of risedronate for the treatment of postmenopausal 
osteoporosis. Endocr Rev 2002;23:517-523. 
36. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Adachi J, Wells G, Shea 
B, Guyatt G. Meta-analyses of therapies for postmenopausal osteoporosis. IV. 
Meta-analysis of raloxifene for the prevention and treatment of postmenopausal 
osteoporosis. Endocr Rev 2002;23:524-528. 
37. Cranney A, Tugwell P, Zytaruk N, Robinson V, Weaver B, Shea B, Wells G, Adachi 
J, Waldegger L, Guyatt G. Meta-analyses of therapies for postmenopausal 
osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal 
osteoporosis. Endocr Rev 2002;23:540-551. 
38. Hauselmann HJ, Rizzoli R. A comprehensive review of treatments for 
postmenopausal osteoporosis. Osteoporos lnt 2003;14:2-12. 
39. Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, 
Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD. Effects of oral 
23 
ibandronate administered daily or intermittently on fracture risk in postmenopausal 
osteoporosis. J Bane Miner Res 2004;19:1241-1249. 
40. Andrade SE, Majumdar SR, Chan KA, Buist OS, Go AS, Goodman M, Smith OH, 
Platt R, Gurwitz JH. Law frequency of treatment of osteoporosis among 
postmenopausal women following a fracture. Arch lntern Med 2003;163:2052-
2057. 
41. Bada! P. Questionnaire survey of advice given to patients with fractures. BMJ 
1999;318:500-501. 
42. Kanis JA, Borgstrom F, Johnell 0, Jonsson B. Cost-effectiveness of risedronate for 
the treatment of osteoporosis and prevention of fractures in postmenopausal 
women. Osteoporos lnt 2004 15(11 ):862-871. 
43. Schwenkglenks M, Lippuner K. Simulation-based cost-utility analysis of population 
screening-based alendronate use in Switzerland. Osteoporos lnt 2007; 18: 1481-
1491. 
44. Lamy 0, Krieg MA. The necessity of cost-effectiveness analysis in osteoporosis. 
Rev Med Suisse 2007;3:1521-1525. 
45. Cornuz J, Krieg MA, Burckhardt P. Présentation de l'étude prospective »Evaluation 
suisse des Méthodes de mesure du risque de fracture ostéoporotique». Bulletin 
des médecins suisses 1999;80:352-355. 
46. Krieg MA, Cornuz J, Ruffieux C, Van Melle G, Buche 0, Oambacher MA, Hans 0, 
Hart! F, Hauselmann HJ, Kraenzlin M, Lippuner K, Neff M, Pancaldi P, Rizzoli R, 
Tanzi F, Theiler R, Tyndall A, Wimpfheimer C, Burckhardt P. Prediction of hip 
fracture risk by quantitative ultrasound in more than 7000 Swiss women SO years 
of age: comparison of three technologically different bone ultrasound devices in the 
SEMOF study. J Bane Miner Res 2006;21:1457-1463. 
24 
47. Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone 
mass predict vertebral incidence in women. Ann lntern Med 1991;114:919-923. 
48. Gelbach SH, Bigelow C, Heimisdottir M. Recognition of vertebral fracture in a 
clinical setting. Osteoporosis lnt 2000;11 :577-582. 
49. Cornuz J, Krieg MA, Sandini L, Ruffieux C, van Melle G, Burckhardt P. Factors 
associated with the use of hormone replacement therapy among elderly women. 
Age &Ageing 2003; 32(6): 675-678. 
50. Colditz GA, Martin P, Stampfer MJ. Validation of questionnaire information on risk 
factors and disease outcome in a prospective cohort study of women. Am J 
Epidemiol 1986;123:894-900. 
51. Merlo J, Berglund G, Wirfalt E. Self-administrated questionnaire compared with a 
persona! diary for assessment of current use of hormone therapy: an analysis of 
16060 women. Am J Epidemiol 2000;152:788-92. 
52. Jain MG, Rohan TE, Howe GR. Agreement of self-reported use of menopausal 
hormone replacement therapy with physician reports. Epidemiology.1999;10:260-
263. 
53. Goodman MT, Nomura AMY, Wilkens LR, Kolonel LN. Agreement between 
interview information and physician records on history of menopausal estrogen 
use. Am J Epidemiol 1990;131 :815-825. 
54. Honkanen K, Honkanen R, Heikkinen L, Heikki K, Saarikoski S. Validity of self-
reports of fractures in perimenopausal women. Am J Epidemiol 1999;150:511-516. 
55. Melton LJ, 3rd, Atkinson EJ, Cooper C, O'Fallon WM, Riggs BL. Vertebral fractures 
predict subsequent fractures. Osteoporos lnt 1999;10:214-221. 
56. Johnell 0, Kannus P, Obrant KJ, Jarvinen M, Parkarri. Management of the patient 
after an osteoporotic fracture. Guidelines for orthopedics surgeons- consensus 
25 
conference on Treatment of Osteoporosis for Orthopedic Surgeons, Nordic 
Orthopedic Federation, Tampere, Fin land 2000. Acta Orthop Scand 2001 ;72 
(4):325-330. 
57. Dawson-Hughes B, and the expert committee of the National Osteoporosis 
Foundation 2003 Physician's guide to prevention and treatment of osteoporosis. ln: 
Foundation NO (ed.) 
58. OVO 2006 - Guidelines for prevention, diagnosis, and therapy of osteoporosis for 
women after menopause, for men after age 60: executive summary Dachverband 
Osteologie e.V. 
59. Tang BMP, Eslick GD, Smith C, Bensoussan A. Use of calcium or calcium in 
combination with vitamin D supplementation to prevent fractures and bone loss in 
people aged 50 years and aider: a meta-analysis. Lancet 2007; 370: 657-66. 
26 
